Test Price
2,800 AED✅ Home Collection Available
ALG1 Gene Glycosylation Disorder Type 1K Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
This advanced genetic test offers comprehensive analysis of the ALG1 gene associated with Congenital Disorder of Glycosylation Type Ik (CDG-Ik), utilising DHA-certified Next-Generation Sequencing (NGS) technology. The assay delivers 99.9% diagnostic sensitivity through ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139). Logistics include VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM, complemented by telephonic post-test clinical guidance for result interpretation by DHA-licensed clinicians. Direct billing verification is accessible via WhatsApp at +971 54 548 8731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed clinicians.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The ALG1 Gene Glycosylation Disorder Type 1K Genetic Test detects pathogenic variants in the ALG1 gene responsible for Congenital Disorder of Glycosylation Type Ik (CDG-Ik), a rare autosomal recessive metabolic disorder affecting protein glycosylation pathways critical for multi-organ development. The analysis employs Next-Generation Sequencing to interrogate the entire coding region, splice sites, and flanking intronic regions up to 20 base pairs, ensuring comprehensive variant detection.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Methodology | NGS (Next-Generation Sequencing) | Sanger Sequencing (Single-Exon) |
| Coverage | Full Gene + Splice Sites ±20 bp | Targeted Hotspot Only |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Price | 2800 AED | Variable (Often Higher for Full Gene) |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403): "Genetic evaluation for rare inborn errors of metabolism such as CDG-Ik necessitates thorough pre-test counselling and careful correlation with biochemical phenotypes including transferrin isoform profiling. A negative NGS result does not exclude all congenital glycosylation disorders, and identified variants should be interpreted within the context of the patient's clinical presentation, family pedigree, and functional studies where indicated. I strongly advise every patient to review their results with a board-certified clinical geneticist prior to implementing any health management decisions."
Medication Advisory
Do not discontinue any prescribed medication or alter your treatment regimen without consulting your treating physician. This genetic test serves as a diagnostic adjunct and is not a substitute for ongoing clinical management by your specialist.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals unable to provide informed consent; samples collected outside sterile protocol or improperly stored at ambient temperature exceeding 25 °C for more than 24 hours; neonates younger than 48 hours without paediatrician referral.
- Exclusion: Patients currently on systemic anticoagulant therapy where venipuncture is contraindicated without specialist clearance (applicable to blood draw method).
- ER Red Flag: If the patient experiences unexplained seizures, severe hypotonia, acute liver dysfunction (jaundice, elevated transaminases), or coagulopathy during the diagnostic workup period, seek immediate emergency medical attention — do not wait for genetic test results.
- ER Red Flag: Infants presenting with failure to thrive, recurrent infections, and developmental regression alongside abnormal metabolic screening must be evaluated urgently at a tertiary paediatric centre.
Patient FAQ & Clinical Guidance
1. What exactly does the ALG1 NGS test detect, and how accurate is it for diagnosing CDG Type 1K?
This test sequences the entire coding region of the ALG1 gene using Next-Generation Sequencing technology with 99.9% diagnostic sensitivity, detecting single nucleotide variants, small insertions and deletions, and splice-site mutations that cause Congenital Disorder of Glycosylation Type Ik. The assay covers all exons, intron-exon boundaries, and flanking untranslated regions to maximise detection of disease-causing alterations.
2. What sample types are accepted and how should I prepare for the blood collection?
We accept whole blood collected in EDTA tubes, extracted genomic DNA, or dried blood spots on FTA cards. No fasting is required prior to collection. Patients must complete a pre-test genetic counselling session to document a detailed three-generation family pedigree chart before sample submission. Our mobile phlebotomy team can collect samples at your home between 8 AM and 11 PM daily, with cold-chain transport to the laboratory.
3. Who should consider this test and what does the turnaround time of 3–4 weeks entail?
Individuals with clinical suspicion of CDG-Ik — including unexplained developmental delay, hypotonia, coagulopathy, or abnormal transferrin isoform analysis — should consider this test. The 3-to-4-week turnaround time encompasses DNA extraction, library preparation, NGS sequencing, bioinformatic analysis, variant classification, and multidisciplinary clinical review of all identified variants before report release.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Accreditation
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All genomic data is encrypted, stored within UAE sovereign data centres, and processed exclusively under DHA-audited bioinformatics pipelines. Patient genetic data is never shared with third parties without explicit written consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Electronic health records and genetic test data are managed in compliance with UAE ICT security standards for healthcare information systems.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical testing procedures and patient consent protocols follow the UAE framework for medical responsibility and patient rights.
- ISO 9001:2015 Certification: INT/EGQ/2509DA/3139 — Quality Management System certified for molecular diagnostics and clinical genomics.
- DHA Facility License: 1143 — Laboratory operations are conducted under the regulatory oversight of the Dubai Health Authority.
Clinical & Logistical Metadata
| Test Name | ALG1 Gene Glycosylation Disorder Type 1K Genetic Test (NGS) |
| Price (AED) | 2800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage with Splice Site Analysis |
| ICD-10-CM Code | E77.8 (Other disorders of glycoprotein metabolism) |
| LOINC Code | 50398-0 (ALG1 gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians